ALK (ALKB.DC / OMX: ALK B) will publish its results for the first nine months (Q3) of 2025 in the morning on Thursday, 13 November 2025. Later on the same day, the company will host a presentation for investors and analysts at 1:30 p.m. CET, where ALK’s management will comment on the results for the first nine months and the outlook and be available for questions. ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR. Live audio webcast The m ...

Group 1 - ALK will publish its results for the first six months of 2025 on 21 August 2025, followed by a presentation for investors and analysts at 1:30 p.m. CEST [1] - The presentation will be available on ALK's website shortly before the meeting starts [4] - The meeting will be audio webcasted live and available for replay on ALK's website [2] Group 2 - Participants can join the conference call by registering through a provided link and will receive dial-in details via email [3] - ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma, employing around 2,800 people worldwide [6] - The company is headquartered in Hørsholm, Denmark, and is listed on Nasdaq Copenhagen [6]

Core Viewpoint - ALK has upgraded its full-year financial outlook for 2025 due to higher-than-expected revenue in Europe and an improved outlook for the remainder of the year [1][2]. Group 1: Financial Performance - Total revenue for Q2 grew by 12% in local currencies, reaching DKK 1,527 million, compared to DKK 1,374 million in the previous year [3]. - EBIT increased by 41% in local currencies to DKK 375 million, resulting in an EBIT margin of 25% [3]. - The revenue growth forecast has been revised to 12-14% in local currencies, up from the previous estimate of 9-13% [8]. Group 2: Market Dynamics - Q2 performance was positively influenced by sales of adrenaline autoinjectors and strong momentum for tablets in Europe, which is expected to continue in the second half of the year [2]. - There is anticipated solid growth in tablet sales in North America, contributing to the overall positive outlook [2]. - The updated forecast reflects reduced risks associated with market conditions in Europe for the remainder of the year [2]. Group 3: Strategic Investments - Based on the improved revenue outlook, ALK plans to allocate additional funds to strategic growth investments in the second half of the year [2].

Group 1 - ALK will publish its Q1 2025 results on May 6, 2025, and will host an investor presentation at 11:00 a.m. CEST the same day [1] - The presentation will be available for live audio webcast and replay on ALK's website [2] - Participants can register for the conference call via a provided link and will receive dial-in details via email [3] Group 2 - ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma, headquartered in Hørsholm, Denmark, employing around 2,800 people [6]